{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:44:47Z","timestamp":1790754287009,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T00:00:00Z","timestamp":1666483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T00:00:00Z","timestamp":1666483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"DAAD\/NRF","award":["57343411"],"award-info":[{"award-number":["57343411"]}]},{"DOI":"10.13039\/100020306","name":"Steigerwald Arzneimittelwerk","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020306","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008769","name":"Julius-Maximilians-Universit\u00e4t W\u00fcrzburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pyrrolizidine alkaloids (PAs) are secondary plant metabolites, which can be found as contaminant in various foods and herbal products. Several PAs can cause hepatotoxicity and liver cancer via damaging hepatic sinusoidal endothelial cells (HSECs) after hepatic metabolization. HSECs themselves do not express the required metabolic enzymes for activation of PAs. Here we applied a co-culture model to mimic the in vivo hepatic environment and to study PA-induced effects on not metabolically active neighbour cells. In this co-culture model, bioactivation of PA was enabled by metabolically capable human hepatoma cells HepG2, which excrete the toxic and mutagenic pyrrole metabolites. The human cervical epithelial HeLa cells tagged with H2B-GFP were utilized as non-metabolically active neighbours because they can be identified easily based on their green fluorescence in the co-culture. The PAs europine, riddelliine and lasiocarpine induced micronuclei in HepG2 cells, and in HeLa H2B-GFP cells co-cultured with HepG2 cells, but not in HeLa H2B-GFP cells cultured alone. Metabolic inhibition of cytochrome P450 enzymes with ketoconazole abrogated micronucleus formation. The efflux transporter inhibitors verapamil and benzbromarone reduced micronucleus formation in the co-culture model. Furthermore, mitotic disturbances as an additional genotoxic mechanism of action were observed in HepG2 cells and in HeLa H2B-GFP cells co-cultured with HepG2 cells, but not in HeLa H2B-GFP cells cultured alone. Overall, we were able to show that PAs were activated by HepG2 cells and the metabolites induced genomic damage in co-cultured HeLa cells.<\/jats:p>","DOI":"10.1007\/s00204-022-03394-z","type":"journal-article","created":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T15:02:37Z","timestamp":1666537357000},"page":"295-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Genotoxicity of pyrrolizidine alkaloids in metabolically inactive human cervical cancer HeLa cells co-cultured with human hepatoma HepG2 cells"],"prefix":"10.1007","volume":"97","author":[{"given":"Naji Said Aboud","family":"Hadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7488-6228","authenticated-orcid":false,"given":"Ezgi Eyluel","family":"Bankoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Stopper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,23]]},"reference":[{"issue":"2","key":"3394_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10565-021-09599-9","volume":"38","author":"S Abdelfatah","year":"2022","unstructured":"Abdelfatah S, Na\u00df J, Knorz C, Klauck SM, K\u00fcpper J-H, Efferth T (2022) Pyrrolizidine alkaloids cause cell cycle and DNA damage repair defects as analyzed by transcriptomics in cytochrome P450 3A4-overexpressing HepG2 clone 9 cells. Cell Biol Toxicol 38(2):325\u2013345","journal-title":"Cell Biol Toxicol"},{"key":"3394_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.fct.2018.08.003","volume":"121","author":"A Allemang","year":"2018","unstructured":"Allemang A, Mahony C, Lester C, Pfuhler S (2018) Relative potency of fifteen pyrrolizidine alkaloids to induce DNA damage as measured by micronucleus induction in HepaRG human liver cells. Food Chem Toxicol 121:72\u201381","journal-title":"Food Chem Toxicol"},{"issue":"12","key":"3394_CR3","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/j.2042-7158.2012.01562.x","volume":"64","author":"N Araki","year":"2012","unstructured":"Araki N, Tsuruoka S, Hasegawa G et al (2012) Inhibition of CYP3A4 by 6\u2019,7\u2019-dihydroxybergamottin in human CYP3A4 over-expressed hepG2 cells. J Pharm Pharmacol 64(12):1715\u20131721. https:\/\/doi.org\/10.1111\/j.2042-7158.2012.01562.x","journal-title":"J Pharm Pharmacol"},{"key":"3394_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2020.152628","volume":"447","author":"E Arzuk","year":"2020","unstructured":"Arzuk E, Karaku\u015f F, Orhan H (2020) Bioactivation of clozapine by mitochondria of the murine heart: Possible cause of cardiotoxicity. Toxicology 447:152628. https:\/\/doi.org\/10.1016\/j.tox.2020.152628","journal-title":"Toxicology"},{"issue":"2","key":"3394_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00412-018-0660-2","volume":"127","author":"NC Baudoin","year":"2018","unstructured":"Baudoin NC, Cimini D (2018) A guide to classifying mitotic stages and mitotic defects in fixed cells. Chromosoma 127(2):215\u2013227. https:\/\/doi.org\/10.1007\/s00412-018-0660-2","journal-title":"Chromosoma"},{"issue":"8","key":"3394_CR6","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1023\/a:1025040712857","volume":"20","author":"B Bauer","year":"2003","unstructured":"Bauer B, Miller DS, Fricker G (2003) Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system. Pharm Res 20(8):1170\u20131176. https:\/\/doi.org\/10.1023\/a:1025040712857","journal-title":"Pharm Res"},{"issue":"2","key":"3394_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/s0027-5107(96)00240-0","volume":"374","author":"R Botta","year":"1997","unstructured":"Botta R, Gustavino B (1997) Relationship between chromatin bridges in anaphase and chromosomal aberrations induced by TMP + UVA (365 nm) in CHO cells. Mutat Res 374(2):253\u2013259. https:\/\/doi.org\/10.1016\/s0027-5107(96)00240-0","journal-title":"Mutat Res"},{"issue":"11","key":"3394_CR8","first-page":"2406","volume":"9","author":"Chain EPoCitF,","year":"2011","unstructured":"Chain EPoCitF, (2011) Scientific opinion on pyrrolizidine alkaloids in food and feed. EFSA J 9(11):2406","journal-title":"EFSA J"},{"issue":"3","key":"3394_CR9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jat.1504","volume":"30","author":"T Chen","year":"2010","unstructured":"Chen T, Mei N, Fu PP (2010) Genotoxicity of pyrrolizidine alkaloids. J Appl Toxicol 30(3):183\u2013196","journal-title":"J Appl Toxicol"},{"key":"3394_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.fct.2019.05.024","volume":"130","author":"L Chen","year":"2019","unstructured":"Chen L, Mulder PP, Peijnenburg A, Rietjens IM (2019) Risk assessment of intake of pyrrolizidine alkaloids from herbal teas and medicines following realistic exposure scenarios. Food Chem Toxicol 130:142\u2013153","journal-title":"Food Chem Toxicol"},{"issue":"3","key":"3394_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/s0168-8278(03)00231-9","volume":"39","author":"M Chojkier","year":"2003","unstructured":"Chojkier M (2003) Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J Hepatol 39(3):437\u2013446. https:\/\/doi.org\/10.1016\/s0168-8278(03)00231-9","journal-title":"J Hepatol"},{"issue":"1","key":"3394_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1055\/s-2002-23204","volume":"22","author":"LD Deleve","year":"2002","unstructured":"Deleve LD, Shulman HM, McDonald GB (2002) Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22(1):27\u201342. https:\/\/doi.org\/10.1055\/s-2002-23204","journal-title":"Semin Liver Dis"},{"issue":"3","key":"3394_CR13","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/s0016-5085(03)01056-4","volume":"125","author":"LD Deleve","year":"2003","unstructured":"Deleve LD, Wang X, Tsai J, Kanel G, Strasberg S, Tokes ZA (2003) Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology 125(3):882\u2013890. https:\/\/doi.org\/10.1016\/s0016-5085(03)01056-4","journal-title":"Gastroenterology"},{"key":"3394_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-4939-2074-7_5","volume-title":"Culture and functional characterization of human hepatoma HepG2 cells protocols in in vitro hepatocyte research","author":"MT Donato","year":"2015","unstructured":"Donato MT, Tolosa L, G\u00f3mez-Lech\u00f3n MJ (2015) Culture and functional characterization of human hepatoma HepG2 cells protocols in in vitro hepatocyte research. Springer, pp 77\u201393"},{"issue":"4","key":"3394_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00280-010-1385-y","volume":"67","author":"Y Donmez","year":"2011","unstructured":"Donmez Y, Akhmetova L, Iseri OD, Kars MD, Gunduz U (2011) Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells. Cancer Chemother Pharmacol 67(4):823\u2013828. https:\/\/doi.org\/10.1007\/s00280-010-1385-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"3394_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.fct.2019.05.019","volume":"130","author":"J Ebmeyer","year":"2019","unstructured":"Ebmeyer J, Braeuning A, Glatt H, These A, Hessel-Pras S, Lampen A (2019) Human CYP3A4-mediated toxification of the pyrrolizidine alkaloid lasiocarpine. Food Chem Toxicol 130:79\u201388. https:\/\/doi.org\/10.1016\/j.fct.2019.05.019","journal-title":"Food Chem Toxicol"},{"issue":"1","key":"3394_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1021\/tx500403t","volume":"28","author":"JA Edgar","year":"2015","unstructured":"Edgar JA, Molyneux RJ, Colegate SM (2015) Pyrrolizidine alkaloids: potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease. Chem Res Toxicol 28(1):4\u201320. https:\/\/doi.org\/10.1021\/tx500403t","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"3394_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.18433\/j3sg66","volume":"11","author":"ME Elsherbiny","year":"2008","unstructured":"Elsherbiny ME, El-Kadi AO, Brocks DR (2008) The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci 11(1):147\u2013159. https:\/\/doi.org\/10.18433\/j3sg66","journal-title":"J Pharm Pharm Sci"},{"issue":"8","key":"3394_CR19","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1021\/bi9718043","volume":"37","author":"M Essodaigui","year":"1998","unstructured":"Essodaigui M, Broxterman HJ, Garnier-Suillerot A (1998) Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry 37(8):2243\u20132250. https:\/\/doi.org\/10.1021\/bi9718043","journal-title":"Biochemistry"},{"key":"3394_CR20","unstructured":"European Medicines Agency (2021) Public statement on the use of herbal medicinal products containing toxic, unsaturated pyrrolizidine alkaloids (PAs) including recommendations regarding contamination of herbal medicinal products with PAs. In. https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/public-statement-use-herbal-medicinal-products-containing-toxic-unsaturated-pyrrolizidine-alkaloids_en-0.pdf"},{"issue":"3","key":"3394_CR21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1054\/bjoc.2000.1260","volume":"83","author":"R Evers","year":"2000","unstructured":"Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Borst P (2000) Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 83(3):366\u2013374. https:\/\/doi.org\/10.1054\/bjoc.2000.1260","journal-title":"Br J Cancer"},{"key":"3394_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.toxicon.2015.02.001","volume":"97","author":"RA Field","year":"2015","unstructured":"Field RA, Stegelmeier BL, Colegate SM, Brown AW, Green BT (2015) An in vitro comparison of the cytotoxic potential of selected dehydropyrrolizidine alkaloids and some N-oxides. Toxicon 97:36\u201345. https:\/\/doi.org\/10.1016\/j.toxicon.2015.02.001","journal-title":"Toxicon"},{"issue":"1","key":"3394_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1081\/dmr-120028426","volume":"36","author":"PP Fu","year":"2004","unstructured":"Fu PP, Xia Q, Lin G, Chou MW (2004) Pyrrolizidine alkaloids\u2013genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 36(1):1\u201355. https:\/\/doi.org\/10.1081\/dmr-120028426","journal-title":"Drug Metab Rev"},{"key":"3394_CR24","doi-asserted-by":"publisher","DOI":"10.38212\/2224-6614.2392","author":"PP Fu","year":"2007","unstructured":"Fu PP, Xia Q, Chou MW, Lin G (2007) Detection, hepatotoxicity, and tumorigenicity of pyrrolizidine alkaloids in Chinese herbal plants and herbal dietary supplements. J Food Drug Anal. https:\/\/doi.org\/10.38212\/2224-6614.2392","journal-title":"J Food Drug Anal"},{"key":"3394_CR25","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.2147\/DDDT.S87858","volume":"9","author":"H Gao","year":"2015","unstructured":"Gao H, Ruan JQ, Chen J et al (2015) Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug Des Devel Ther 9:4861\u20134868. https:\/\/doi.org\/10.2147\/DDDT.S87858","journal-title":"Drug Des Devel Ther"},{"key":"3394_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2019.110868","volume":"135","author":"I Geburek","year":"2020","unstructured":"Geburek I, Preiss-Weigert A, Lahrssen-Wiederholt M, Schrenk D, These A (2020) In vitro metabolism of pyrrolizidine alkaloids\u2013Metabolic degradation and GSH conjugate formation of different structure types. Food Chem Toxicol 135:110868","journal-title":"Food Chem Toxicol"},{"issue":"2","key":"3394_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10565-011-9208-4","volume":"28","author":"HH Gerets","year":"2012","unstructured":"Gerets HH, Tilmant K, Gerin B et al (2012) Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 28(2):69\u201387. https:\/\/doi.org\/10.1007\/s10565-011-9208-4","journal-title":"Cell Biol Toxicol"},{"key":"3394_CR70","unstructured":"Giacomini KM, Sugiyama Y (2015) Membrane transporters and drug response. Brunton LL, Chabner BA, Knollmann BC (Eds.), Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e. McGraw Hill. https:\/\/accessmedicine.mhmedical.com\/content.aspx?bookid=1613&sectionid=102157524"},{"issue":"1","key":"3394_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/cpdd.100","volume":"3","author":"DJ Greenblatt","year":"2014","unstructured":"Greenblatt DJ (2014) The ketoconazole legacy. Clin Pharmacol Drug Dev 3(1):1\u20133. https:\/\/doi.org\/10.1002\/cpdd.100","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"3394_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/jcph.609","volume":"56","author":"DJ Greenblatt","year":"2016","unstructured":"Greenblatt DJ (2016) Evidence-based choice of ritonavir as index CYP3A inhibitor in drug-drug interaction studies. J Clin Pharmacol 56(2):152\u2013156. https:\/\/doi.org\/10.1002\/jcph.609","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"3394_CR30","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1002\/jcph.400","volume":"54","author":"HK Greenblatt","year":"2014","unstructured":"Greenblatt HK, Greenblatt DJ (2014) Liver injury associated with ketoconazole: review of the published evidence. J Clin Pharmacol 54(12):1321\u20131329. https:\/\/doi.org\/10.1002\/jcph.400","journal-title":"J Clin Pharmacol"},{"key":"3394_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrgentox.2020.503305","volume":"861\u2013862","author":"NSA Hadi","year":"2021","unstructured":"Hadi NSA, Bankoglu EE, Schott L et al (2021) Genotoxicity of selected pyrrolizidine alkaloids in human hepatoma cell lines HepG2 and Huh6. Mutat Res 861\u2013862:503305. https:\/\/doi.org\/10.1016\/j.mrgentox.2020.503305","journal-title":"Mutat Res"},{"issue":"1","key":"3394_CR32","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/hep.31723","volume":"74","author":"Y He","year":"2021","unstructured":"He Y, Shi M, Wu X et al (2021a) Mutational signature analysis reveals widespread contribution of pyrrolizidine alkaloid exposure to human liver cancer. Hepatology 74(1):264\u2013280","journal-title":"Hepatology"},{"issue":"6","key":"3394_CR33","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00204-021-03060-w","volume":"95","author":"Y He","year":"2021","unstructured":"He Y, Zhu L, Ma J, Lin G (2021b) Metabolism-mediated cytotoxicity and genotoxicity of pyrrolizidine alkaloids. Arch Toxicol 95(6):1917\u20131942","journal-title":"Arch Toxicol"},{"issue":"1","key":"3394_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00204-019-02582-8","volume":"94","author":"S Hessel-Pras","year":"2020","unstructured":"Hessel-Pras S, Braeuning A, Guenther G et al (2020) The pyrrolizidine alkaloid senecionine induces CYP-dependent destruction of sinusoidal endothelial cells and cholestasis in mice. Arch Toxicol 94(1):219\u2013229","journal-title":"Arch Toxicol"},{"issue":"1","key":"3394_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0041-008X(91)90137-4","volume":"111","author":"JR Hincks","year":"1991","unstructured":"Hincks JR, Kim H-Y, Segall H, Molyneux RJ, Stermitz FR, Coulombe RA Jr (1991) DNA cross-linking in mammalian cells by pyrrolizidine alkaloids: structure-activity relationships. Toxicol Appl Pharmacol 111(1):90\u201398","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"3394_CR36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clpt.2005.05.011","volume":"78","author":"RH Ho","year":"2005","unstructured":"Ho RH, Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78(3):260\u2013277. https:\/\/doi.org\/10.1016\/j.clpt.2005.05.011","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"3394_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00412-004-0284-6","volume":"112","author":"DR Hoffelder","year":"2004","unstructured":"Hoffelder DR, Luo L, Burke NA, Watkins SC, Gollin SM, Saunders WS (2004) Resolution of anaphase bridges in cancer cells. Chromosoma 112(8):389\u2013397","journal-title":"Chromosoma"},{"issue":"1","key":"3394_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/mutage\/geq062","volume":"26","author":"Y Huang","year":"2011","unstructured":"Huang Y, Fenech M, Shi Q (2011) Micronucleus formation detected by live-cell imaging. Mutagenesis 26(1):133\u2013138","journal-title":"Mutagenesis"},{"key":"3394_CR39","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fphar.2018.00646","volume":"9","author":"J Huang","year":"2018","unstructured":"Huang J, Guo L, Tan R et al (2018) Interactions between emodin and efflux transporters on rat enterocyte by a validated ussing chamber technique. Front Pharmacol 9:646. https:\/\/doi.org\/10.3389\/fphar.2018.00646","journal-title":"Front Pharmacol"},{"key":"3394_CR40","unstructured":"Huisman MTJS, Monbaliu J, Martens M, Sekar V, Raoof A (2010) in_vitro_studies_investigating_the_mechanism_of_interaction_between_tmc435_and_hepatic_transporters_2010.pdf. Poster presented at the 61st AASLD Meeting, Boston, MA, USA"},{"issue":"2","key":"3394_CR41","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.tiv.2009.10.009","volume":"24","author":"K Jemnitz","year":"2010","unstructured":"Jemnitz K, Veres Z, Tugyi R, Vereczkey L (2010) Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes. Toxicol in Vitro 24(2):605\u2013610. https:\/\/doi.org\/10.1016\/j.tiv.2009.10.009","journal-title":"Toxicol in Vitro"},{"key":"3394_CR42","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1021\/jf0114482","volume":"50","author":"A John","year":"2002","unstructured":"John A, Edgar ER, Molyneux RJ (2002) Honey from plants containing pyrrolizidine alkaloids: a potential threat to health. J Agric Food Chem 50:2719\u20132730","journal-title":"J Agric Food Chem"},{"key":"3394_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2010\/313280","volume":"2010","author":"F Kakar","year":"2010","unstructured":"Kakar F, Akbarian Z, Leslie T et al (2010) An outbreak of hepatic veno-occlusive disease in Western Afghanistan associated with exposure to wheat flour contaminated with pyrrolizidine alkaloids. J Toxicol 2010:1\u20137","journal-title":"J Toxicol"},{"issue":"12","key":"3394_CR44","doi-asserted-by":"publisher","first-page":"4914","DOI":"10.1002\/jps.21756","volume":"98","author":"AS Kalgutkar","year":"2009","unstructured":"Kalgutkar AS, Frederick KS, Chupka J et al (2009) N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a \u201cchemical knock-out equivalent\u201d to assess the impact of efflux transporters on oral drug absorption in the rat. J Pharm Sci 98(12):4914\u20134927. https:\/\/doi.org\/10.1002\/jps.21756","journal-title":"J Pharm Sci"},{"issue":"7","key":"3394_CR45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0960-9822(98)70156-3","volume":"8","author":"T Kanda","year":"1998","unstructured":"Kanda T, Sullivan KF, Wahl GM (1998) Histone\u2013GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. Curr Biol 8(7):377\u2013385","journal-title":"Curr Biol"},{"issue":"1\u20132","key":"3394_CR46","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejps.2012.02.016","volume":"46","author":"H Kidron","year":"2012","unstructured":"Kidron H, Wissel G, Manevski N et al (2012) Impact of probe compound in MRP2 vesicular transport assays. Eur J Pharm Sci 46(1\u20132):100\u2013105. https:\/\/doi.org\/10.1016\/j.ejps.2012.02.016","journal-title":"Eur J Pharm Sci"},{"issue":"7","key":"3394_CR47","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1124\/dmd.113.056689","volume":"42","author":"L Li","year":"2014","unstructured":"Li L, Tu M, Yang X et al (2014) The contribution of human OCT1, OCT3, and CYP3A4 to nitidine chloride-induced hepatocellular toxicity. Drug Metab Dispos 42(7):1227\u20131234. https:\/\/doi.org\/10.1124\/dmd.113.056689","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"3394_CR48","first-page":"181","volume":"26","author":"G Lin","year":"1998","unstructured":"Lin G, Cui Y-Y, Hawes EM (1998) Microsomal formation of a pyrrolic alcohol glutathione conjugate of clivorine: firm evidence for the formation of a pyrrolic metabolite of an otonecine-type pyrrolizidine alkaloid. Drug Metab Dispos 26(2):181\u2013184","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"3394_CR49","first-page":"1475","volume":"28","author":"G Lin","year":"2000","unstructured":"Lin G, Cui Y-Y, Hawes EM (2000) Characterization of rat liver microsomal metabolites of clivorine, an hepatotoxic otonecine-type pyrrolizidine alkaloid. Drug Metab Dispos 28(12):1475\u20131483","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"3394_CR50","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jhep.2010.07.031","volume":"54","author":"G Lin","year":"2011","unstructured":"Lin G, Wang JY, Li N et al (2011) Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol 54(4):666\u2013673. https:\/\/doi.org\/10.1016\/j.jhep.2010.07.031","journal-title":"J Hepatol"},{"key":"3394_CR51","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4103\/2277-9175.183664","volume":"5","author":"M Louisa","year":"2016","unstructured":"Louisa M, Suyatna FD, Wanandi SI, Asih PB, Syafruddin D (2016) Differential expression of several drug transporter genes in HepG2 and Huh-7 cell lines. Adv Biomed Res 5:104. https:\/\/doi.org\/10.4103\/2277-9175.183664","journal-title":"Adv Biomed Res"},{"key":"3394_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2019.05.040","volume":"131","author":"J Louisse","year":"2019","unstructured":"Louisse J, Rijkers D, Stoopen G et al (2019) Determination of genotoxic potencies of pyrrolizidine alkaloids in HepaRG cells using the gammaH2AX assay. Food Chem Toxicol 131:110532. https:\/\/doi.org\/10.1016\/j.fct.2019.05.040","journal-title":"Food Chem Toxicol"},{"key":"3394_CR53","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.fct.2019.04.057","volume":"129","author":"Y Lu","year":"2019","unstructured":"Lu Y, Ma J, Lin G (2019) Development of a two-layer transwell co-culture model for the in vitro investigation of pyrrolizidine alkaloid-induced hepatic sinusoidal damage. Food Chem Toxicol 129:391\u2013398. https:\/\/doi.org\/10.1016\/j.fct.2019.04.057","journal-title":"Food Chem Toxicol"},{"issue":"6","key":"3394_CR54","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1021\/acs.chemrestox.8b00369","volume":"32","author":"J Ma","year":"2019","unstructured":"Ma J, Ruan J, Chen X et al (2019) Pyrrole\u2013hemoglobin adducts, a more feasible potential biomarker of pyrrolizidine alkaloid exposure. Chem Res Toxicol 32(6):1027\u20131039","journal-title":"Chem Res Toxicol"},{"issue":"2","key":"3394_CR55","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00204-020-02947-4","volume":"95","author":"J Ma","year":"2021","unstructured":"Ma J, Zhang W, He Y et al (2021) Clinical application of pyrrole\u2013hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans. Arch Toxicol 95(2):759\u2013765","journal-title":"Arch Toxicol"},{"key":"3394_CR56","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.biopha.2018.05.127","volume":"105","author":"L Mohan","year":"2018","unstructured":"Mohan L, Raghav D, Ashraf SM, Sebastian J, Rathinasamy K (2018) Indirubin, a bis-indole alkaloid binds to tubulin and exhibits antimitotic activity against HeLa cells in synergism with vinblastine. Biomed Pharmacother 105:506\u2013517","journal-title":"Biomed Pharmacother"},{"key":"3394_CR57","first-page":"51","volume":"47","author":"CFG Muller","year":"1995","unstructured":"Muller CFG, Ferrandis E, Cornil-Scharwtz I, Bailly JD, Bordier C, Benard J, Sikic BI, Laurent G (1995) Evidence for transcriptional control of human MDR l gene expression by verapamil in Multidrug-resistant leukimic cells by MULLER 1995.pdf. Mol Pharmacol 47:51\u201356","journal-title":"Mol Pharmacol"},{"issue":"1","key":"3394_CR58","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11172-017-1713-z","volume":"66","author":"SV Nikulin","year":"2017","unstructured":"Nikulin SV, Tonevitsky EA, Poloznikova AA (2017) Effect of ketoconazole on the transport and metabolism of drugs in the human liver cell model. Russ Chem Bull 66(1):150\u2013155","journal-title":"Russ Chem Bull"},{"key":"3394_CR59","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2174\/138945006777709593","volume":"7","author":"SIL Nobili","year":"2006","unstructured":"Nobili SIL, Giglioni B, Mini E (2006) Pharmacological Strategies for overcoming multidrug resistance by nobili2006.pdf. Curr Drug Targets 7:861\u2013879","journal-title":"Curr Drug Targets"},{"issue":"10","key":"3394_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111286","volume":"9","author":"A Novotna","year":"2014","unstructured":"Novotna A, Krasulova K, Bartonkova I et al (2014) Dual effects of ketoconazole cis-enantiomers on CYP3A4 in human hepatocytes and HepG2 Cells. PLoS ONE 9(10):e111286. https:\/\/doi.org\/10.1371\/journal.pone.0111286","journal-title":"PLoS ONE"},{"issue":"11","key":"3394_CR61","first-page":"1303","volume":"28","author":"K Ohyama","year":"2000","unstructured":"Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T (2000) A significant role of human cytochrome P450 2C8 in Amiodarone <em>N<\/em>-Deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 28(11):1303\u20131310","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"3394_CR62","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00204-008-0332-8","volume":"82","author":"O Pelkonen","year":"2008","unstructured":"Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H (2008) Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82(10):667\u2013715. https:\/\/doi.org\/10.1007\/s00204-008-0332-8","journal-title":"Arch Toxicol"},{"issue":"10","key":"3394_CR63","doi-asserted-by":"publisher","first-page":"2772","DOI":"10.1105\/tpc.104.023176","volume":"16","author":"A Reimann","year":"2004","unstructured":"Reimann A, Nurhayati N, Backenkohler A, Ober D (2004) Repeated evolution of the pyrrolizidine alkaloid-mediated defense system in separate angiosperm lineages. Plant Cell 16(10):2772\u20132784. https:\/\/doi.org\/10.1105\/tpc.104.023176","journal-title":"Plant Cell"},{"issue":"10","key":"3394_CR64","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1007\/s00204-020-02840-0","volume":"94","author":"H Reimann","year":"2020","unstructured":"Reimann H, Stopper H, Hintzsche H (2020) Long-term fate of etoposide-induced micronuclei and micronucleated cells in Hela-H2B-GFP cells. Arch Toxicol 94(10):3553\u20133561","journal-title":"Arch Toxicol"},{"key":"3394_CR65","first-page":"1","volume":"018","author":"Risk-Assessment FIf","year":"2013","unstructured":"Risk-Assessment FIf (2013) Pyrrolizidine alkaloids in herbal teas and teas. BfR Berlin (germany) 018:1\u201329","journal-title":"BfR Berlin (germany)"},{"issue":"1","key":"3394_CR66","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1006\/excr.1993.1295","volume":"209","author":"M Rizzoni","year":"1993","unstructured":"Rizzoni M, Cundari E, Perticone P, Gustavino B (1993) Chromatin bridges between sister chromatids induced in late G2 mitosis in CHO cells by trimethylpsoralen+ UVA. Exp Cell Res 209(1):149\u2013155","journal-title":"Exp Cell Res"},{"issue":"4","key":"3394_CR67","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/10590501.2015.1096882","volume":"33","author":"J Ruan","year":"2015","unstructured":"Ruan J, Gao H, Li N et al (2015) Blood pyrrole-protein adducts\u2013A biomarker of pyrrolizidine alkaloid-induced liver injury in humans. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 33(4):404\u2013421. https:\/\/doi.org\/10.1080\/10590501.2015.1096882","journal-title":"J Environ Sci Health C Environ Carcinog Ecotoxicol Rev"},{"issue":"4","key":"3394_CR68","first-page":"437","volume":"2","author":"DS Sinclair","year":"1975","unstructured":"Sinclair DS, Fox IH (1975) The pharmacology of hypouricemic effect of benzbromarone. J Rheumatol 2(4):437\u2013445","journal-title":"J Rheumatol"},{"issue":"1","key":"3394_CR69","first-page":"95","volume":"8","author":"B Stegelmeier","year":"1999","unstructured":"Stegelmeier B, Edgar J, Colegate S et al (1999) Pyrrolizidine alkaloid plants, metabolism and toxicity. J Nat Toxins 8(1):95\u2013116","journal-title":"J Nat Toxins"},{"key":"3394_CR71","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ejps.2018.07.017","volume":"122","author":"GN Tocchetti","year":"2018","unstructured":"Tocchetti GN, Dominguez CJ, Zecchinati F et al (2018) Inhibition of multidrug resistance-associated protein 2 (MRP2) activity by the contraceptive nomegestrol acetate in HepG2 and Caco-2 cells. Eur J Pharm Sci 122:205\u2013213. https:\/\/doi.org\/10.1016\/j.ejps.2018.07.017","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"3394_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010089","volume":"5","author":"K-i Utani","year":"2010","unstructured":"Utani K-i, Kohno Y, Okamoto A, Shimizu N (2010) Emergence of micronuclei and their effects on the fate of cells under replication stress. PLoS ONE 5(4):e10089","journal-title":"PLoS ONE"},{"issue":"2","key":"3394_CR73","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","volume":"38","author":"K Venkatakrishnan","year":"2000","unstructured":"Venkatakrishnan K, von Moltke LL, Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism by venkatakrishnan2000pdf. Clin Pharmacokinet 38(2):111\u2013180","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3394_CR74","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1124\/dmd.115.067744","volume":"44","author":"LM Vermeer","year":"2016","unstructured":"Vermeer LM, Isringhausen CD, Ogilvie BW, Buckley DB (2016) Evaluation of ketoconazole and its alternative clinical CYP3A4\/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters. Drug Metab Dispos 44(3):453\u2013459. https:\/\/doi.org\/10.1124\/dmd.115.067744","journal-title":"Drug Metab Dispos"},{"key":"3394_CR75","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-3-319-13278-5","volume-title":"DNA damaging drugs Molecular therapies of cancer","author":"GF Weber","year":"2015","unstructured":"Weber GF (2015) DNA damaging drugs Molecular therapies of cancer. Springer, pp 9\u2013112"},{"issue":"3","key":"3394_CR76","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1211\/002235702739","volume":"55","author":"JL Weemhoff","year":"2003","unstructured":"Weemhoff JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol 55(3):381\u2013386. https:\/\/doi.org\/10.1211\/002235702739","journal-title":"J Pharm Pharmacol"},{"issue":"8","key":"3394_CR77","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.tiv.2007.05.014","volume":"21","author":"WM Westerink","year":"2007","unstructured":"Westerink WM, Schoonen WG (2007) Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol Vitro 21(8):1581\u20131591. https:\/\/doi.org\/10.1016\/j.tiv.2007.05.014","journal-title":"Toxicol Vitro"},{"issue":"9","key":"3394_CR78","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1021\/tx400241c","volume":"26","author":"Q Xia","year":"2013","unstructured":"Xia Q, Zhao Y, Von Tungeln LS et al (2013) Pyrrolizidine alkaloid-derived DNA adducts as a common biological biomarker of pyrrolizidine alkaloid-induced tumorigenicity. Chem Res Toxicol 26(9):1384\u20131396","journal-title":"Chem Res Toxicol"},{"key":"3394_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2018.10.009","author":"QX Xiaobo He","year":"2018","unstructured":"Xiaobo He QX, Qiangen Wu, Tolleson WH, Lin Ge, Fu PP (2018) Primary and Secondary pyrrolic metabolites of pyrrolizidine alkaloids form DNA adducts in human A549 cells. Toxicol Vitro. https:\/\/doi.org\/10.1016\/j.tiv.2018.10.009","journal-title":"Toxicol Vitro"},{"issue":"3\u20134","key":"3394_CR80","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.livres.2019.11.004","volume":"3","author":"J Xu","year":"2019","unstructured":"Xu J, Wang W, Yang X, Xiong A, Yang L, Wang Z (2019) Pyrrolizidine alkaloids: an update on their metabolism and hepatotoxicity mechanism. Liver Research 3(3\u20134):176\u2013184","journal-title":"Liver Research"},{"issue":"12","key":"3394_CR81","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1007\/s00204-017-2013-y","volume":"91","author":"M Yang","year":"2017","unstructured":"Yang M, Ruan J, Gao H et al (2017) First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans. Arch Toxicol 91(12):3913\u20133925. https:\/\/doi.org\/10.1007\/s00204-017-2013-y","journal-title":"Arch Toxicol"},{"issue":"1","key":"3394_CR82","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s13318-016-0323-8","volume":"42","author":"H Zhang","year":"2017","unstructured":"Zhang H, Ya G, Rui H (2017) Inhibitory effects of triptolide on human liver cytochrome P450 enzymes and P-Glycoprotein. Eur J Drug Metab Pharmacokinet 42(1):89\u201398. https:\/\/doi.org\/10.1007\/s13318-016-0323-8","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"3394_CR83","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00204-016-1713-z","volume":"91","author":"L Zhu","year":"2017","unstructured":"Zhu L, Xue J, Xia Q, Fu PP, Lin G (2017) The long persistence of pyrrolizidine alkaloid-derived DNA adducts in vivo: kinetic study following single and multiple exposures in male ICR mice. Arch Toxicol 91(2):949\u2013965","journal-title":"Arch Toxicol"},{"key":"3394_CR84","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.foodcont.2017.10.026","volume":"85","author":"L Zhu","year":"2018","unstructured":"Zhu L, Wang Z, Wong L et al (2018) Contamination of hepatotoxic pyrrolizidine alkaloids in retail honey in China. Food Control 85:484\u2013494","journal-title":"Food Control"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-022-03394-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-022-03394-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-022-03394-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T12:03:52Z","timestamp":1701259432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-022-03394-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,23]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3394"],"URL":"https:\/\/doi.org\/10.1007\/s00204-022-03394-z","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,23]]},"assertion":[{"value":"16 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}